CDC25A and triple-negative breast carcinoma: In triple-negative breast cancer models, KLT effectively blocked cell cycle progression at the G2/M phase by downregulating CDK1, CDK2, and CHEK1, inhibiting CDC25A, CDC25B, MELK, and AURKA activity, suppressing mitosis, and inducing apoptosis (112).